Blockade of the renin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To test if the renin-angiotensin-aldosterone system (RAAS) is involved in growth hormone (GH)-associated fluid retention, the researchers examined the effect of GH administration in the presence or absence of RAAS blockade at different levels on body fluid homeostasis.

Why It Was Studied

Eight subjects were examined in a controlled, randomized double-blinded trial.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

PubMed files the paper under topics including Blood Pressure, Body Fluids, Heart Rate, Homeostasis, Human Growth Hormone, Insulin and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1997 (The American journal of physiology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.